Durable platelet response and immature platelet indices following sequential efgartigimod and eltrombopag therapy in a patient with refractory ITP.
Fumiya Wada, Hiroyuki Matsui, Takuji Nakamura et al.
✦ AI-curated · Sources linked
Case in brief
A patient with refractory immune thrombocytopenia (ITP) received efgartigimod, which led to a partial platelet response. This response was further enhanced by the addition of eltrombopag, resulting in durable remission even after discontinuation of efgartigimod. Hematologic analysis showed changes in immature platelet indices, indicating a potential biomarker for monitoring treatment response.
What made this case unusual
The case highlights the reciprocal shift in immature platelet indices during treatment, with a decrease in immature platelet fraction percentage and an increase in absolute immature platelet fraction, suggesting their potential as biomarkers in ITP management.
Diagnostic / clinical pearl
Clinicians should consider monitoring immature platelet indices as potential biomarkers for assessing treatment response in patients with refractory ITP undergoing combination therapy.
Why it matters
This case underscores the importance of understanding the immunomodulatory effects of FcRn inhibition and its synergy with TPO receptor agonists in managing refractory ITP.